The central nervous disorders therapeutics market generated $1,17,556.10 million in 2020 and is projected to reach $2,32,294.20 million by 2030, growing at a CAGR of 7.3% from 2021 to 2030.
The central nervous system (CNS) is a complex system that regulates and coordinates body activities. Central nervous system (CNS) disorders, also known as central nervous system diseases. It is a group of neurological disorders that affect structure and function of brain and spinal cord. The group of disorder including tumors that cause delayed puberty. However, CNS disorders such as neurodegenerative diseases, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, autoimmune & inflammatory diseases, genetic disorders, cancers, and others affect structure and function of the brain or spinal cord. Thus, CNS treatment are used to treat these disorders.
The central nervous disorders therapeutics market is anticipated to grow substantially during the forecast period, owing to rise in case of chronic diseases such as neurovascular diseases, degenerative diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, infectious diseases, mental health, anxiety disorders, bipolar disorder, and depression. Moreover, increase in geriatric population is one of the major factors that drives the market growth. Hence, these factors further augment the central nervous disorders therapeutics market.
Over the years, central nervous disorders therapeutics market has shown huge growth due to advancements in diagnostics, treatment, and drug discovery techniques. Moreover, increase in demand for effective CNS treatment and therapeutic options encourage major pharmaceutical companies to invest in R&D, thus creating future growth opportunities. In addition, rise in awareness regarding treatment of neurovascular diseases, degenerative diseases, infectious diseases, and mental health, surge in prevalence of lifestyle-associated CNS disorders propel growth of the central nervous disorders therapeutics market.
Furthermore, increase in prevalence of CNS disorders and presence of strong pipeline drugs are some of the factors, which are projected to offer huge growth opportunities in the future. In addition, introduction of a novel drug delivery systems in CNS also offers ample growth opportunities to the central nervous disorders therapeutics market.
The central nervous disorders therapeutics market is classified on the basis of disease, distribution channel, age group, and region. By disease, the market is divided into neurovascular diseases, degenerative diseases (Alzheimer's diseases, Parkinson's disease, multiple sclerosis, and others), infectious diseases, mental health (anxiety disorders, bipolar disorder, depression, and others), and others. By distribution channel, it is categorized into hospital-based pharmacies, retail pharmacies, and online pharmacies. By age group, it is segmented into pediatric, adult, and geriatric. By region, the market is analyzed across, North America, Europe, Asia-Pacific, and LAMEA.
The central nervous disorders therapeutics market is anticipated to grow substantially during the forecast period, owing to rise in case of chronic diseases such as neurovascular diseases, degenerative diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, infectious diseases, mental health, anxiety disorders, bipolar disorder, and depression. Moreover, increase in geriatric population is one of the major factors that drives the market growth. Hence, these factors further augment the central nervous disorders therapeutics market.
Over the years, central nervous disorders therapeutics market has shown huge growth due to advancements in diagnostics, treatment, and drug discovery techniques. Moreover, increase in demand for effective CNS treatment and therapeutic options encourage major pharmaceutical companies to invest in R&D, thus creating future growth opportunities. In addition, rise in awareness regarding treatment of neurovascular diseases, degenerative diseases, infectious diseases, and mental health, surge in prevalence of lifestyle-associated CNS disorders propel growth of the central nervous disorders therapeutics market.
Furthermore, increase in prevalence of CNS disorders and presence of strong pipeline drugs are some of the factors, which are projected to offer huge growth opportunities in the future. In addition, introduction of a novel drug delivery systems in CNS also offers ample growth opportunities to the central nervous disorders therapeutics market.
The central nervous disorders therapeutics market is classified on the basis of disease, distribution channel, age group, and region. By disease, the market is divided into neurovascular diseases, degenerative diseases (Alzheimer's diseases, Parkinson's disease, multiple sclerosis, and others), infectious diseases, mental health (anxiety disorders, bipolar disorder, depression, and others), and others. By distribution channel, it is categorized into hospital-based pharmacies, retail pharmacies, and online pharmacies. By age group, it is segmented into pediatric, adult, and geriatric. By region, the market is analyzed across, North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the central nervous disorders therapeutics market, and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2020 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analysed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Disease
- Neurovascular Diseases
- Degenerative Diseases
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Mental Health
- Anxiety Disorders
- Bipolar Disorder
- Depression
- Others
- Others
By Distribution Channel
- Hospital Based Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Age Group
- Pediatric
- Adult
- Geriatric
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- Biogen
- Otsuka Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- Merck & Co.
- Astra Zeneca
- Shire PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.3. Top positioning players
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing Prevalence of CNS Disorders
3.4.1.2. Presence of Strong Pipeline Drugs
3.4.2. Restraints
3.4.2.1. High treatment cost
3.4.3. Opportunity
3.4.3.1. Introduction of a Novel Drug Delivery Systems in CNS
3.5. COVID-19 impact on the global central nervous system disorder treatment market
CHAPTER 4: CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE4.1. Overview
4.1.1. Market size and forecast
4.2. Neurovascular Diseases
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Degenerative Diseases
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Alzheimer's Disease
4.3.2.1.1. Market size and forecast
4.3.2.2. Parkinson's Disease
4.3.2.2.1. Market size and forecast
4.3.2.3. Multiple Sclerosis
4.3.2.3.1. Market size and forecast
4.3.2.4. Others
4.3.2.4.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
4.4. Mental Health
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by type
4.4.2.1. Psychotic disorder
4.4.2.1.1. Market size and forecast
4.4.2.2. Epilepsy
4.4.2.2.1. Market size and forecast
4.4.2.3. Depression
4.4.2.3.1. Market size and forecast
4.4.2.4. Others
4.4.2.4.1. Market size and forecast
4.4.3. Market size and forecast, by region
4.4.4. Market analysis, by country
4.5. Infectious Diseases
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Others Disease
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
CHAPTER 5: CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital-based pharmacies
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Retail pharmacy
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Online Pharmacy
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
CHAPTER 6: CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Adults
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Geriatric
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY REGION7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. central nervous disorders therapeutics market, by disease
7.2.2.1.2. Sciential nervous disorders therapeutics market, by distribution channel
7.2.2.1.3. U.S. central nervous disorders therapeutics market, by age group
7.2.2.2. Canada
7.2.2.2.1. Canada central nervous disorders therapeutics market, by disease
7.2.2.2.2. Canada central nervous disorders therapeutics market, by distribution channel
7.2.2.2.3. Canada central nervous disorders therapeutics market, by age group
7.2.2.3. Mexico
7.2.2.3.1. Mexico central nervous disorders therapeutics market, by disease
7.2.2.3.2. Mexico central nervous disorders therapeutics market, by distribution channel
7.2.2.3.3. Mexico central nervous disorders therapeutics market by age group
7.2.3. North America market size and forecast, by disease
7.2.4. North America market size and forecast, by distribution channel
7.2.5. North America market size and forecast, by age group
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany central nervous disorders therapeutics market, by disease
7.3.2.1.2. Germany central nervous disorders therapeutics market, by distribution channel
7.3.2.1.3. Germany central nervous disorders therapeutics market, by age group
7.3.2.2. France
7.3.2.2.1. France central nervous disorders therapeutics market, by disease
7.3.2.2.2. France central nervous disorders therapeutics market, by distribution channel
7.3.2.2.3. France central nervous disorders therapeutics market, by age group
7.3.2.3. UK
7.3.2.3.1. UK central nervous disorders therapeutics market, by disease
7.3.2.3.2. UK central nervous disorders therapeutics market, by distribution channel
7.3.2.3.3. UK central nervous disorders therapeutics market, by age group
7.3.2.4. Italy
7.3.2.4.1. Italy central nervous disorders therapeutics market, by disease
7.3.2.4.2. Italy central nervous disorders therapeutics market, by distribution channel
7.3.2.4.3. Italy central nervous disorders therapeutics market, by age group
7.3.2.5. Spain
7.3.2.5.1. Spain central nervous disorders therapeutics market, by disease
7.3.2.5.2. Spain central nervous disorders therapeutics market, by distribution channel
7.3.2.5.3. Spain central nervous disorders therapeutics market, by age group
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe central nervous disorders therapeutics market, by disease
7.3.2.6.2. Rest of Europe central nervous disorders therapeutics market, by distribution channel
7.3.2.6.3. Rest of Europe central nervous disorders therapeutics market, by age group
7.3.3. Europe market size and forecast, by disease
7.3.4. Europe market size and forecast, by distribution channel
7.3.5. Europe market size and forecast, by age group
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan central nervous disorders therapeutics market, by disease
7.4.2.1.2. Japan central nervous disorders therapeutics market, by distribution channel
7.4.2.1.3. Japan central nervous disorders therapeutics market, by age group
7.4.2.2. China
7.4.2.2.1. China central nervous disorders therapeutics market , by disease
7.4.2.2.2. China central nervous disorders therapeutics market , by distribution channel
7.4.2.2.3. China central nervous disorders therapeutics market , by age group
7.4.2.3. Australia
7.4.2.3.1. Australia central nervous disorders therapeutics market, by disease
7.4.2.3.2. Australia central nervous disorders therapeutics market, by distribution channel
7.4.2.3.3. Australia central nervous disorders therapeutics market, by age group
7.4.2.4. India
7.4.2.4.1. India central nervous disorders therapeutics market, by disease
7.4.2.4.2. India central nervous disorders therapeutics market, by distribution channel
7.4.2.4.3. India central nervous disorders therapeutics market, by age group
7.4.2.5. South Korea
7.4.2.5.1. South Korea central nervous disorders therapeutics market, by disease
7.4.2.5.2. South Korea central nervous disorders therapeutics market, by distribution channel
7.4.2.5.3. South Korea central nervous disorders therapeutics market, by age group
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific central nervous disorders therapeutics market, by disease
7.4.2.6.2. Rest of Asia-Pacific central nervous disorders therapeutics market, by distribution channel
7.4.2.6.3. Rest of Asia-Pacific central nervous disorders therapeutics market, by age group
7.4.3. Asia-Pacific market size and forecast, by disease
7.4.4. Asia-Pacific market size and forecast, by distribution channel
7.4.5. Asia-Pacific market size and forecast, by age group
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil central nervous disorders therapeutics market, by disease
7.5.2.1.2. Brazil central nervous disorders therapeutics market, by distribution channel
7.5.2.1.3. Brazil central nervous disorders therapeutics market, by age group
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia central nervous disorders therapeutics market, by disease
7.5.2.2.2. Saudi Arabia central nervous disorders therapeutics market, by distribution channel
7.5.2.2.3. Saudi Arabia central nervous disorders therapeutics market, by age group
7.5.2.3. South Africa
7.5.2.3.1. South Africa central nervous disorders therapeutics market, by disease
7.5.2.3.2. South Africa central nervous disorders therapeutics market, by distribution channel
7.5.2.3.3. South Africa central nervous disorders therapeutics market, by age group
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA central nervous disorders therapeutics market, by disease
7.5.2.4.2. Rest of LAMEA central nervous disorders therapeutics market, by distribution channel
7.5.2.4.3. Rest of LAMEA central nervous disorders therapeutics market, by age group
7.5.3. LAMEA market size and forecast, by disease
7.5.4. LAMEA market size and forecast, by distribution channel
7.5.5. LAMEA market size and forecast, by age group
CHAPTER 8: COMPANY PROFILES8.1. AstraZeneca PLC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance
8.2. Biogen, Inc
8.2.1. Company overview
8.2.2. Operating business segments
8.2.3. Product portfolio
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. Eli Lily and Company.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.1. Operating business segments
8.3.2. Product portfolio
8.3.3. Business performance
8.3.4. Key strategic moves and developments
8.4. Johnson & Johnson
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Merck & Co., Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Novartis AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Ostuka Pharmaceuticals Ltd
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. PFIZER INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Teva Pharmaceuticals, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 02. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR NUEROVASCULAR DISEASE, BY REGION, 2020-2030 ($MILLION)
TABLE 03. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENERATIVE DISEASE, BY TYPE, 2020-2030 ($MILLION)
TABLE 04. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENRATIVE DISEASE, BY REGION, 2020-2030 ($MILLION)
TABLE 05. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH, BY TYPE, 2020-2030 ($MILLION)
TABLE 06. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2020-2030 ($MILLION)
TABLE 08. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET OTHERS FOR MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09. GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 10. HOSPITAL-BASED PHARMACIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
TABLE 12. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ONLINE PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 13. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 14. CENTRAL NERVOUS DISORDERS THERAPEUTICS FOR PEDIARTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 15. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ADULTS, BY REGION, 2020-2030 ($MILLION)
TABLE 16. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR GERIARTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKEGLOBAL, BY REGION, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 19. U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 20. U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 21. U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 22. CANADA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 23. CANADA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 24. MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 25. MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 26. MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 27. NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 28. NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 29. NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 30. EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31. GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 32. GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 33. GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 34. FRANCE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 35. FRANCE L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 36. FRANCE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 37. UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 38. UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 39. UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 40. ITALY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 41. ITALY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 42. ITALY L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 43. SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 44. SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 45. SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 47. REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 48. REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 49. EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 50. EUROPE L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 51. EUROPE G CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53. JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 54. JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 55. JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 56. CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY DISEASE, 2020-2030 ($MILLION)
TABLE 57. CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 58. CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 59. AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 62. INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 63. INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 64. INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 65. SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 66. SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 67. SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 71. ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 72. ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 73. ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 74. LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 75. BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 76. BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 77. BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 78. SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 79. SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 80. SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 81. SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 82. SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 83. SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 84. REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 85. REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 86. REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 87. LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 88. LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 89. LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 90. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 91. ASTRAZENECA: OPERATING SEGMENTS
TABLE 92. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 93. BIOGEN: COMPANY SNAPSHOT
TABLE 94. BIOGEN: OPERATING SEGMENTS
TABLE 95. BIOGEN: PRODUCT PORTFOLIO
TABLE 96. ELI LILLY: COMPANY SNAPSHOT
TABLE 97. ELI LILLY: OPERATING SEGMENTS
TABLE 98. ELLI-LILLY: PRODUCT PORTFOLIO
TABLE 99. J&J: COMPANY SNAPSHOT
TABLE 100. J&J: OPERATING SEGMENTS
TABLE 101. J&J: PRODUCT PORTFOLIO
TABLE 102. MERCK.: COMPANY SNAPSHOT
TABLE 103. MERCK.: OPERATING SEGMENTS
TABLE 104. MERCK & CO.: PRODUCT PORTFOLIO
TABLE 105. NOVARTIS: COMPANY SNAPSHOT
TABLE 106. NOVARTIS: OPERATING SEGMENTS
TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 108. OSTUKA: COMPANY SNAPSHOT
TABLE 109. OSTUKA PHARMACEUTICALS LTD.: OPERATING SEGMENTS
TABLE 110. OSTUK PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 111. PFIZER: COMPANY SNAPSHOT
TABLE 112. PFIZER: OPERATING SEGMENTS
TABLE 113. PFIZER: PRODUCT PORTFOLIO
TABLE 114. SHIRE: COMPANY SNAPSHOT
TABLE 115. SHIRE: OPERATING SEGMENTS
TABLE 116. SHIRE: PRODUCT PORTFOLIO
TABLE 117. TEVA: COMPANY SNAPSHOT
TABLE 118. TEVA: OPERATING SEGMENTS
TABLE 119. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET: SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2021-2030
FIGURE 04. TOP WINNING STRATEGIES:BY DEVELOPMENT, 2021-2030
FIGURE 05. TOP WINNING STRATEGIES: BY COMPANY, 2021-2030 (%)
FIGURE 06. TOP POSITIONING PLYAERS, 2021-2030
FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
FIGURE 09. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. MODRATE THREAT OF NEW ENTRANT
FIGURE 12. HIGH COMPETITIVE RIVALRY
FIGURE 13. MARKET DYNAMICS
FIGURE 14. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR NUEROVASCUALR DISEASE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ALZHEIMER'S DISEASE MARKET, 2020-2030 ($MILLION)
FIGURE 16. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR PARKINSON’S DISEASE, 2020-2030 ($MILLION)
FIGURE 17. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MULTIPLE SCLEROSIS, 2020-2030 ($MILLION)
FIGURE 18. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS, 2020-2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENRATIVE DISEASE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR PSYCOTIC DISORDER, 2020-2030 ($MILLION)
FIGURE 21. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ANXIETY, 2020-2030 ($MILLION)
FIGURE 22. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEPRESSION, 2020-2030 ($MILLION)
FIGURE 23. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS, 2020-2030 ($MILLION)
FIGURE 24. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25. COMPARATIVE ANALYSIS OF I CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR INFECTIOUS DISEASE, MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 27. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR HOSPITAL-BASED PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 28. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 29. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 30. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR PEDIARTIC (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 31. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ADULT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 32. COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS GERIARTIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 33. ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36. BIOGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. BIOGEN REVENUE SHARE BY REGIONT, 2020 (%)
FIGURE 38. NET SALES, 2018-2020 ($MILLION)
FIGURE 39. ELI LILLY REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40. ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41. NET SALES, 2018-2020 ($MILLION)
FIGURE 42. J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. J&J: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 44. NET SALES, 2018-2020 ($MILLION)
FIGURE 45. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 47. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 48. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 49. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 50. PFIZER NET SALES, 2019-2020 ($MILLION)
FIGURE 51. PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 52. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 53. TEVA: NET SALES, 2018-2020 ($MILLION)
FIGURE 54. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55. TEVA: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- Biogen
- Otsuka Pharmaceutical Co. Ltd.
- Eli Lilly and Company
- Merck & Co.
- Astra Zeneca
- Shire PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 274 |
| Published | August 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 117556.1 million |
| Forecasted Market Value ( USD | $ 232294.2 million |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
